A PSMA-targeted NIR agent (named OTL78) showed a tumour-to-muscle ranging from 19–25 after 2 h post administration [40], while IRDye700DX-PSMA showed a tumour-to-muscle of 30 at 4 h post administration and more than 50 at 24 h. The gene discussed is FOLH1; the disease is neoplasm.